What is the 13F Pro Quality Score for UPB?

13F Pro ranks Upstream Bio, Inc. (UPB) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View UPB's current score at https://13fpro.ai/research/UPB (free sign-up required for the full ranking).

Which hedge funds own the most UPB stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of UPB include FMR, ORBIMED ADVISORS, BlackRock,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/UPB as soon as new 13F filings post.

Where does 13F Pro source UPB data?

All Upstream Bio, Inc. fundamentals and ownership data come directly from SEC EDGAR. Upstream Bio, Inc. files with the SEC under CIK 2022626. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is UPB in?

Upstream Bio, Inc. (UPB) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is UPB research updated on 13F Pro?

UPB's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Upstream Bio, Inc.(UPB)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 2022626 UPB stock profile & AI dashboard →

13F Pro Quality Score

22.6/100

Rank #2,633 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

97.5/100

Profitability

1.0/100

Balance Sheet

4.8/100

Earnings Quality

30.0/100

Free Cash Flow

0.7/100

Institutional Flow

5.0/100

Revenue Scale

1.5/100

Dilution Risk

1.4/100

UPB Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Upstream Bio, Inc. (UPB), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores UPB at 22.6/100 on a 32-signal composite quality model, placing it at rank #2,633 of 2,879 stocks — the bottom half of the AI-ranked universe. UPB scores in the top quartile across revenue growth (97.5). Areas of concern include free cash flow (0.7) and profitability (1.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 1.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Upstream Bio, Inc. reports quarterly revenue of $1.0M, net income of $-40.6M, free cash flow of $-47.9M. Top institutional holders of UPB by reported 13-F value include FMR, ORBIMED ADVISORS, BlackRock,, based on the most recent SEC filings. UPB trades on the Nasdaq exchange and files with the SEC under CIK 2022626. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate UPB daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Upstream Bio, Inc. directly from SEC EDGAR. Upstream Bio, Inc.'s 13F Pro composite quality score has ranged between 17 and 26 since 2025, currently 22.6 — a declining long-term trajectory across 12 quarterly and live scoring snapshots.

Revenue

Q1 2026

$1.0M

Net Income

Q1 2026

$-40.6M

Free Cash Flow

Q1 2026

$-47.9M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+20.4% YoY

$2.9MFY 2025

FY23 $2.4MFY24 $2.4MFY25 $2.9M

Net Income

-128.4% YoY

$-143.4MFY 2025

FY23 $-20.5MFY24 $-62.8MFY25 $-143.4M

Operating Income

-106.2% YoY

$-160.4MFY 2025

FY23 $-40.1MFY24 $-77.8MFY25 $-160.4M

EPS (Diluted)

+52.3% YoY

$-2.66FY 2025

FY23 $-12.35FY24 $-5.58FY25 $-2.66

Total Assets

-26.6% YoY

$353.8MFY 2025

FY23 $117.2MFY24 $481.7MFY25 $353.8M

Op. Cash Flow

-125.2% YoY

$-133.3MFY 2025

FY23 $-37.9MFY24 $-59.2MFY25 $-133.3M

Metric	FY 2025	FY 2024	FY 2023
Revenue	$2.9M +20.4%	$2.4M -0.4%	$2.4M
Net Income	$-143.4M -128.4%	$-62.8M -205.8%	$-20.5M
Operating Income	$-160.4M -106.2%	$-77.8M -93.9%	$-40.1M
EPS (Diluted)	$-2.66 +52.3%	$-5.58 +54.8%	$-12.35
Total Assets	$353.8M -26.6%	$481.7M +311.0%	$117.2M
Operating Cash Flow	$-133.3M -125.2%	$-59.2M -56.0%	$-37.9M

AI Insight: UPB Financial Trends

Upstream Bio is burning through equity at an accelerating pace with no revenue growth and deteriorating cash flow, having depleted $166M in shareholder value over 9 months.

• Revenue flat at $1M across all seven quarters; no meaningful commercial traction.

• Operating cash burn worsened to -$48M in Q1 2026, up 166% from -$20M in Q4 2024.

• Equity declined 35% from $470M (Q4 2024) to $304M (Q1 2026) as losses accumulate.

⚠ Operating losses expanded to -$46M in Q1 2026; if burn rate holds, runway may be constrained.

⚠ Net income losses remain severe and volatile (range -$21M to -$42M); no path to profitability visible.

AI Insight: UPB Ratio Trends

Upstream Bio's profitability metrics have deteriorated sharply across all return measures, with Q1 2026 ROIC at -57.4%, the worst in the dataset.

• ROE worsened from -18.1% in Q4 2024 to -53.4% in Q1 2026, signaling sustained unprofitability and capital destruction.

• ROIC declined from -22.4% in Q4 2024 to -57.4% in Q1 2026, indicating the company is burning capital across all operations.

• ROA fell from -17.6% in Q4 2024 to -51.0% in Q1 2026, reflecting accelerating losses relative to asset base.

⚠ Q2 2025 marked a peak deterioration (ROE -39.1%, ROIC -43.4%) before partial recovery in Q3 2025, then renewed decline into Q1 2026.

⚠ TTM metrics now exceed individual quarter losses (TTM ROIC -56.6% vs. Q1 2026 -57.4%), suggesting sustained burn with no improvement trajectory.

Get alerted when UPB's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Upstream Bio, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of UPB

FMR LLC
$72.9M8,101,563 sh
ORBIMED ADVISORS LLC
$51.2M5,693,589 sh
BlackRock, Inc.
$30.3M3,370,689 sh
Decheng Capital LLC
$24.5M2,724,868 sh
Enavate Sciences GP, LLC
$22.1M2,459,703 sh
VANGUARD CAPITAL MANAGEMENT LLC
$16.9M1,873,574 sh
Y-Intercept (Hong Kong) Ltd
$9.0M1,000,631 sh
FEDERATED HERMES, INC.
$8.8M979,758 sh
GEODE CAPITAL MANAGEMENT, LLC
$8.6M950,617 sh
MILLENNIUM MANAGEMENT LLC
$8.4M937,323 sh

Fund	Value	Shares
FMR LLC	$72.9M	8,101,563
ORBIMED ADVISORS LLC	$51.2M	5,693,589
BlackRock, Inc.	$30.3M	3,370,689
Decheng Capital LLC	$24.5M	2,724,868
Enavate Sciences GP, LLC	$22.1M	2,459,703
VANGUARD CAPITAL MANAGEMENT LLC	$16.9M	1,873,574
Y-Intercept (Hong Kong) Ltd	$9.0M	1,000,631
FEDERATED HERMES, INC.	$8.8M	979,758
GEODE CAPITAL MANAGEMENT, LLC	$8.6M	950,617
MILLENNIUM MANAGEMENT LLC	$8.4M	937,323

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put UPB on your watchlist

Track score changes the day Upstream Bio, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is UPB a good stock to buy?

13F Pro's AI-powered analysis of Upstream Bio, Inc. (UPB) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for UPB are available on the UPB stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own UPB?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling UPB. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Upstream Bio, Inc.'s investment landscape.